Obesity (Silver Spring, Md.) · 2026
Safety and Effectiveness of Metabolic and Bariatric Procedures in Heart Failure: A Multicenter Retrospective Cohort Study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ostrominski John W, Schwede Madeleine, Lodi Jenna, Jirapinyo Pichamol, Spector David, Sheu Eric G, Platz Elke
Аннотация
OBJECTIVE: This study examined the safety and effectiveness of metabolic and bariatric procedures (MBPs), including surgical and endoscopic interventions, among individuals with versus without heart failure (HF).
METHODS: This multicenter retrospective cohort study (2021-2023) identified persons with HF who underwent MBPs at two medical centers. Thirty-day safety events and changes in body weight and medication use were assessed.
RESULTS: Of 1678 MBPs, 41 (2.4%) were performed in adults with HF (mean age, 51 ± 15 years; 66% female; mean BMI, 44 ± 7 kg/m2). Despite older age and more obesity-related complications, persons with HF did not appear to experience a higher risk of any safety event at 30 days versus those without HF (24% vs. 16%; adjusted OR, 1.64; 95% CI, 0.76-3.58; p = 0.21). Thirty-day change in body weight was similar between those with (-5.9%; 95% CI, -6.9%, -4.9%) and without HF (-6.2%; 95% CI, -6.4%, -6.0%; p comparison = 0.57). By 1 year, individuals with HF experienced significant reductions in body weight (mean change, -18.7%; 95% CI, -22.1%, -15.3%; p < 0.001), cardiovascular (p = 0.003) and glucose-lowering medications (p < 0.001), and loop diuretics (p = 0.003).
CONCLUSIONS: These findings suggest that MBPs are safe and effective in well-selected adults with obesity and HF. However, larger and prospective studies are warranted to enhance understanding of MBP risk/benefit in this population.
METHODS: This multicenter retrospective cohort study (2021-2023) identified persons with HF who underwent MBPs at two medical centers. Thirty-day safety events and changes in body weight and medication use were assessed.
RESULTS: Of 1678 MBPs, 41 (2.4%) were performed in adults with HF (mean age, 51 ± 15 years; 66% female; mean BMI, 44 ± 7 kg/m2). Despite older age and more obesity-related complications, persons with HF did not appear to experience a higher risk of any safety event at 30 days versus those without HF (24% vs. 16%; adjusted OR, 1.64; 95% CI, 0.76-3.58; p = 0.21). Thirty-day change in body weight was similar between those with (-5.9%; 95% CI, -6.9%, -4.9%) and without HF (-6.2%; 95% CI, -6.4%, -6.0%; p comparison = 0.57). By 1 year, individuals with HF experienced significant reductions in body weight (mean change, -18.7%; 95% CI, -22.1%, -15.3%; p < 0.001), cardiovascular (p = 0.003) and glucose-lowering medications (p < 0.001), and loop diuretics (p = 0.003).
CONCLUSIONS: These findings suggest that MBPs are safe and effective in well-selected adults with obesity and HF. However, larger and prospective studies are warranted to enhance understanding of MBP risk/benefit in this population.